Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops oral small molecule therapies for neuroscience, inflammation, and immunology (NI&I) indications. The company's lead wholly-owned asset, PIPE-791, is a brain-penetrant small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF) and chronic pain. Its second clinical candidate, PIPE-307, is a selective inhibitor of the muscarinic type 1 receptor (M1R) being developed for major depressive disorder and relapsing-remitting multiple sclerosis, in collaboration with Johnson & Johnson. Headquartered in San Diego, California, Contineum aims to address the underlying mechanisms of disease progression to slow or halt disease activity.
